文献速递神经免疫

累积奥瑞珠单抗暴露对多发性硬化记忆B细胞再增殖动力学的影响

Effect of Cumulative Exposure to Ocrelizumab on Memory B-Cell Repopulation Dynamics in Multiple Sclerosis.
PubMed 文献 · Ann Neurol · 2025-06-11

研究纳入101例多发性硬化患者,采用记忆B细胞引导的延长间隔奥瑞珠单抗方案,收集1369份样本。发现距上次输注时间越长,CD19+和记忆B细胞计数越高;累积剂量越大,记忆B细胞持续耗竭越明显。年龄和性别也影响再增殖动力学。

要点

  • 累积奥瑞珠单抗剂量越高,记忆B细胞再增殖越慢。
  • 距上次输注时间与B细胞再增殖正相关。
  • 年龄较大和女性与B细胞再增殖动力学相关。

核心结论

  • 记忆B细胞再增殖随累积奥瑞珠单抗剂量增加而减慢。
  • 年龄和性别相关机制可能影响再增殖动力学。

研究设计与样本

  • 研究为多发性硬化患者队列,采用记忆B细胞引导的延长间隔奥瑞珠单抗方案。
  • 共收集101例患者的1369份样本,61.4%为女性,年龄42.2岁(IQR 32.3-51.1),随访4.1年(IQR 2.9-5.2)。

主要发现

  • 距上次输注时间与CD19+ B细胞计数正相关(RR=1.11,95%CI 1.10-1.11,p<0.001)。
  • 距上次输注时间与CD19+CD27+记忆B细胞计数正相关(RR=1.11,95%CI 1.09-1.13,p<0.001)。
  • 累积奥瑞珠单抗剂量越大,CD19+CD27+记忆B细胞持续耗竭越明显(OR=1.90,95%CI 1.57-2.31,p<0.001)。
  • CD19+ B细胞再增殖与年龄负相关(RR=0.82,95%CI 0.71-0.95,p=0.010)。
  • 女性患者CD19+CD27+记忆B细胞/总CD19+ B细胞比值较低(RR=0.42,95%CI 0.26-0.69,p=0.001)。

临床怎么用

  • 制定奥瑞珠单抗延长间隔方案时可考虑累积剂量对记忆B细胞再增殖的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Extended interval dosing protocols of B-cell-depleting therapies in multiple sclerosis (MS) are being developed, but intervals between infusions are often arbitrary. We describe total and memory B-cell repopulation dynamics in MS patients on a memory B-cell-guided extended interval dosing ocrelizumab (OCR) protocol. METHODS: OCR was administered on peripheral CD19+ CD27+ memory B-cell repopulation (≥1 cell/μL), monitored using fluorescence-activated cell sorting. Associations with CD19+ B cells and CD19+ CD27+ memory B cells were tested using mixed-effect hurdle models, with rate ratios (RR) predicting cell counts and odds ratios (OR) predicting cell depletion. RESULTS: We collected 1,369 samples from 101 patients, 61.4% women, aged 42.2 years (IQR 32.3-51.1 years) and follow up 4.1 years (IQR 2.9-5.2 years). The median time between samples and previous OCR infusion was 6.6 months (IQR 4.7-8.8 months). Time since previous OCR infusion was positively associated with CD19+ B cells (RR = 1.11, 95% CI 1.10-1.11, p < 0.001) and CD19+ CD27+ memory B-cell counts (RR = 1.11, 95% CI 1.09-1.13, p < 0.001). A greater cumulative OCR dose was associated with persistent CD19+ CD27+ memory B-cell depletion (OR 1.90, 1.57-2.31, p < 0.001). CD19+ B-cell repopulation was inversely associated with age (RR = 0.82, 95% CI 0.71-0.95, p = 0.010). Female patients showed a lower ratio of CD19+ CD27+ memory B cells/total CD19+ B cells (RR = 0.42, 95% CI 0.26-0.69, p = 0.001). Disease activity was low, with most radiological activity observed within the first year of OCR treatment. INTERPRETATION: Memory B-cell repopulation becomes slower with increasing cumulative OCR dose. Age- and sex-related mechanisms probably influence repopulation dynamics. Given the evidence for a pathogenic role of memory B cells, these observations could be considered when planning extended interval dosing strategies of OCR treatment. ANN NEUROL 2025;98:603-615.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Disanto G, Sacco R, Mallucci G, et al. Effect of Cumulative Exposure to Ocrelizumab on Memory B-Cell Repopulation Dynamics in Multiple Sclerosis. Ann Neurol. 2025. PMID: 40497506. doi:10.1002/ana.27281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。